Bristol-Myers Squibb (BMY) and lung health company Optellum are collaborating to boost early lung cancer diagnosis using artificial intelligence, Optellum said Tuesday.
Under the companies' agreement, Optellum will use its Virtual Nodule Clinic platform at various US health care systems to democratize access to early diagnosis and to evaluate the platform's real-world impact before and after implementation, Optellum said.
The company said the deployments of the platform aim to generate and promote evidence and AI implementation best practices, helping accelerate AI-powered early diagnosis.
Price: 50.30, Change: -1.04, Percent Change: -2.03
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。